neurobopharma.com (NRBO): שווי פעילות לרווח לפני ריבית, מסים ופחת

The price indicator on the NeuroBo Pharmaceuticals (NRBO) chart demonstrates a metric at , which is relevant for a biotech firm developing obesity and diabetes treatments for long-term earnings under patent protection. NeuroBo Pharmaceuticals also invests in neuron regeneration and the fight against metabolic pathologies. Expectations for interim trials of new drugs and partnerships with corporate behemoths support the increase in value.

The EV/EBITDA multiple compares the total enterprise value, including net debt, against operating profit to determine the pre-tax payback period of assets. For NeuroBo Pharmaceuticals (NRBO), this metric is critical, as geopolitical supply chain disruptions and trial delays directly impact EBITDA. By analyzing the historical EV/EBITDA ratio of the business, an investor can distinguish fundamental undervaluation from a systemic liquidity crisis within the company.